ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Able to understand the written informed and able to give informed consent
Locally advanced or metastatic NSCLC with oncogenic driver mutation
Treatment with TKI according to standard of care
Disqualifiers
Unable to draw blood for study purposes
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Erasmus MC Rotterdam Netherlands
Sponsors and collaborators
Erasmus Medical Center
Lead sponsor
Source ClinicalTrials.gov